

Client: Example Client ABC123  
 123 Test Drive  
 Salt Lake City, UT 84108  
 UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 4/24/1990  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Infliximab or Biosimilar Activity and Neutralizing Antibody**

ARUP test code 2008320

**Infliximab Activity**

6.29 ug/mL

INTERPRETIVE INFORMATION: Infliximab or biosimilar Activity, NAB

This test measures the capacity of infliximab to neutralize TNF-alpha activity. Additionally infliximab neutralizing antibodies (NAB) are titered (reporting the minimal serum dilution at which blocking of infliximab activity is no longer observed).

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

Infliximab Activity	Infliximab Neutralizing Ab. Titer	Interpretation
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Detected	A change to another type of therapy (not targeting TNF-alpha) may be appropriate.
0.65 ug/mL or greater	1:20 or greater	Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

**Infliximab Neutralizing Antibody Titer**      **Not Detected**      (Ref Interval: Not Detected)

**H=High, L=Low, \*=Abnormal, C=Critical**

EER Infiximab

See Note

Access ARUP Enhanced Report using either link below:

[Redacted Link]

-Enter Username, Password:  
Username: [Redacted]  
Password: [Redacted]

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Infiximab Activity	18-317-401067	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Infiximab Neutralizing Antibody Titer	18-317-401067	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER Infiximab	18-317-401067	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical